The approval of REBYOTA and SER109 indicated that the direction of microbiome therapy is gradually transitioning from fresh feces to controllable microbiome construction.[15, 59] In the clinicaltrials.gov website, most microbiome‐related clinical trials are focused on CDI treatment.[60] Recently, microbiome therapy toward other pathogenic bacteria has been explored, such as utilization of SynCom for Listeria monocytogenes, Enterococcus, K. pneumoniae and S. Typhimurium elimination.[16, 21, 61] In this study, we designed a tailored functional SynCom for Fn‐infected CRC treatment. The gene discussed is FN1; the disease is colorectal carcinoma.